A novel dominant-negative mutant form of Epstein–Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways
Authors:
- Alexandra MougelAMAlexandra Mougel
- Gautier GoormachtighGGGautier Goormachtigh
- Estelle LoingELEstelle Loing
- VVV
- [Eacute][E[Eacute]
- Ronique FafeurRFRonique Fafeur
- Claude AuriaultCAClaude Auriault
- Jean CollJCJean Coll
- 9 February 2004
- journal article
- Published by Springer Nature in Oncogene
- Vol. 23 (15) , 2681-2693
Abstract
The latent membrane protein-1 (LMP1) is an integral membrane molecule expressed by Epstein-Barr virus (EBV) during viral latency and displays properties of a constitutively activated member of the TNF receptor family. LMP1 is required for B-cell or monocyte immortalization induced by EBV and is sufficient to transform rodent fibroblasts. Transforming potential of LMP1 is mediated by its cytoplasmic C-terminal domain, which activates various cellular signaling pathways including NFkappaB and JNK. In this report, we constructed mutants of LMP1 with preserved membrane spanning domain but mutated in the C-terminal domain and a second truncated C-terminal LMP1 fused to the enhanced green fluorescent protein. This latter mutant, termed LMP1-CT, impairs signaling by ectopic LMP1 as well as endogenous EBV-expressed wild-type (wt) LMP1. In contrast to dominant-negative mutants of LMP1 with preserved membrane spanning domains, LMP1-CT was unable to bind wt LMP1 to form an inactive complex. Its dominant-negative effects were due to binding and sequestration of LMP1 adapters TRAF2 and TRADD as assessed by coimmunoprecipitation experiments and confocal analysis. The effect was selective since LMP1-CT did not inhibit IL-1beta-induced signaling, whereas it impaired TNF-triggered NFkappaB and JNK signals without affecting TNF-induced apoptosis. In addition and in contrast to LMP1 constructs with membrane localization, LMP-CT did not display cytostatic properties in noninfected cells. Importantly, LMP1-CT inhibited survival induced by LMP1 in an EBV-transformed T-cell line expressing the type II viral latency commonly found in the majority of EBV-associated human tumors. These data demonstrate that LMP1-CT is a new tool to explore the differences between LMP1 and TNF signaling and may facilitate the design of molecules with potential therapeutic roles.Keywords
This publication has 37 references indexed in Scilit:
- Signalling pathways of the TNF superfamily: a double-edged swordNature Reviews Immunology, 2003
- Transmembrane Domains 1 and 2 of the Latent Membrane Protein 1 of Epstein-Barr Virus Contain a Lipid Raft Targeting Signal and Play a Critical Role in CytostasisJournal of Virology, 2003
- Role of membrane microdomain rafts in TNFR-mediated signal transductionCell Death & Differentiation, 2003
- LMP1 structure and signal transductionSeminars in Cancer Biology, 2001
- Mechanism of Action of a Novel Latent Membrane Protein-1 Dominant NegativeJournal of Biological Chemistry, 2001
- TUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMSAnnual Review of Immunology, 1999
- Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling MotifsJournal of Biological Chemistry, 1997
- Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expressionEuropean Journal of Immunology, 1995
- Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell deathCell, 1991
- An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cellsCell, 1985